Lv4
560 积分 2022-04-16 加入
Crystal Structure of human FABP4 in complex with 4-(1-methyl-2-phenylindol-3-yl)cyclohexane-1-carboxylic acid
6个月前
已关闭
Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis
8个月前
已完结
Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors
9个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1年前
已完结
Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysi
1年前
已完结
Serum liver fatty acid binding protein shows good correlation with liver histology in NASH
1年前
已关闭
Therapeutic Targeting of Hepatic ACSL4 Ameliorates Non-alcoholic Steatohepatitis in Mice
1年前
已完结
Emerging targets for therapy in ALD: lessons from NASH
2年前
已关闭
Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist
2年前
已完结
Advances in computer-aided drug design for type 2 diabetes
2年前
已完结
Improved quality of life and dyspnea with erdosteine in COVID-19 patients after hospital discharge
皖公网安备34019202002308
